Pediatric Melatonin Linked to Small REM Sleep Reduction

This large propensity-matched polysomnography analysis gives pharmacists the first objective sleep-architecture signal for pediatric melatonin, though its clinical meaning remains uncertain.

melatonindietary supplementspediatric insomniasleep architectureREM sleeppolysomnographypropensity score matchingobservational studyneurologypediatrics Internal Medicine / Hospital Medicine

Background Information

Melatonin may reduce REM sleep in children without affecting total sleep time.

Melatonin is commonly used as a sleep aid in children, yet its impact on sleep architecture using polysomnography (PSG) is not well understood. Outpatient melatonin use in children is associated with a small reduction in the percentage of rapid eye movement (REM) sleep but no differences in total sleep time or other sleep parameters. This study suggests melatonin use affects REM sleep without altering other sleep characteristics, but results might be influenced by residual confounding; further studies on dosage and adherence are needed. Melatonin may slightly reduce REM sleep in children without affecting overall sleep duration or quality.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Juginovic A, Rodman L

Citation: Juginovic A, Rodman L Melatonin Use and Polysomnographic Sleep Architecture in Children. JAMA network open. 2026;9(8):e2626983. doi:10.1001/jamanetworkopen.2026.26983

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →